BrainStorm eyes FDA meeting to find path for rejected ALS drug after withdrawing application

Almost a month after FDA advisers delivered a near-unanimous rejection of BrainStorm Cell Therapeutics’ amyotrophic lateral sclerosis drug, the biotech is looking to sit down with the regulator to map out next steps.